|
|
Article: CytRx: Publication States Chaperone Amplification May Represent a 'Significant Strategy' in Anti-aging Pharmaceutical Design.
- Article from:
- Health & Beauty Close-Up
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 Close-Up Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CytRx Corp., a biopharmaceutical company engaged in molecular chaperone regulation technology, said that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a "significant strategy" in the future design of anti-aging pharmaceuticals.
The paper's authors, led by Stuart K. Calderwood, Ph.D., of Beth Israel Deaconess Medical Center, Harvard Medical School, reviewed 40 clinical and animal studies in peer-reviewed publications and found that molecular chaperones play an important role in the deterrence of protein damage during the aging process and that chaperone expression is required for cell ...